Industrial News_Industrial News_Mabspace Biosciences All rights reserved

顶部联系方式

Time of issue:2018-03-12 00:00:00

Have Any Questions? Mabspace Biosciences Info@mabspacebio.com 迈博斯生物 0512-86861701

搜索

语言切换

Time of issue:2019-11-21 00:00:00



NEWS

Your Current Position:Home

>>

Industrial News



Transcenta Holding Announces Licensing Agreement with Lilly

Time of issue : 2019-11-28 13:26:00

Hong Kong, Suzhou, Hangzhou, China - March 29th, 2019 – Transcenta Holding (Transcenta) today announces that its wholly-owned subsidiary, HJB, has signed an exclusive agreement with Eli Lilly and Company (Lilly) to license a portfolio of novel biotherapeutics programs in the therapeutic area of bone diseases for development and commercialization in Greater China,

See more information

Hong Kong, Suzhou, Hangzhou, China - March 29th, 2019 – Transcenta Holding (Transcenta) today announces that its wholly-owned subsidiary, HJB, has signed an exclusive agreement with Eli Lilly and Company (Lilly) to license a portfolio of novel biotherapeutics programs in the therapeutic area of bone diseases for development and commercialization in Greater China,

Transcenta Holding announces appointment of Dr. Yi Gu as Senior Vice President and Head of Research

Time of issue : 2019-11-28 13:31:00

Suzhou, China – March 11, 2019 – Transcenta Holding(Transcenta), an innovative biotherapeutics company with fully-integrated capabilities in research, development, regulatory and manufacturing, announced today the appointment of Dr. Yi Gu as its Senior Vice President and Head of Research.

See more information

Suzhou, China – March 11, 2019 – Transcenta Holding(Transcenta), an innovative biotherapeutics company with fully-integrated capabilities in research, development, regulatory and manufacturing, announced today the appointment of Dr. Yi Gu as its Senior Vice President and Head of Research.

HJB Merges with MabSpace Biosciences to Form Transcenta Holding, a Fully Integrated Leading Global Biotherapeutics Company

Time of issue : 2019-11-28 13:34:00

HONG KONG, SHANGHAI, SUZHOU and HANGZHOU, China, Jan. 1, 2019 -- HJB and MabSpace Biosciences (MabSpace) today announced that the two companies have entered into a definitive merger agreement to create Transcenta Holding Ltd. (Transcenta), a world-class biotherapeutics company with fully-integrated capabilities in research, development, regulatory and manufacturing of biologics. Dr. Xueming Qian, former Founder, Chairman and CEO of

See more information

HONG KONG, SHANGHAI, SUZHOU and HANGZHOU, China, Jan. 1, 2019 -- HJB and MabSpace Biosciences (MabSpace) today announced that the two companies have entered into a definitive merger agreement to create Transcenta Holding Ltd. (Transcenta), a world-class biotherapeutics company with fully-integrated capabilities in research, development, regulatory and manufacturing of biologics. Dr. Xueming Qian, former Founder, Chairman and CEO of

MabSpace Biosciences Doses First Patient in China Phase 1 Trial for MSB2311 and Submitted IND for MSB0254 to NMPA

Time of issue : 2019-11-28 13:37:00

SUZHOU, China--(BUSINESS WIRE)--MabSpace Biosciences announced that on August 24th, 2018, MSB2311 was successfully administered to the first Chinese cancer patient at Beijing Cancer Hospital in its China Phase 1 trial. MSB2311 is a 2nd-generation PD-L1 antibody with a unique pH-dependent antigen binding property that enables intra-tumor recycling and potentiates tumor penetration.

See more information

SUZHOU, China--(BUSINESS WIRE)--MabSpace Biosciences announced that on August 24th, 2018, MSB2311 was successfully administered to the first Chinese cancer patient at Beijing Cancer Hospital in its China Phase 1 trial. MSB2311 is a 2nd-generation PD-L1 antibody with a unique pH-dependent antigen binding property that enables intra-tumor recycling and potentiates tumor penetration.

Full seat of Village B | Qianbo Ming, CEO of Maibos Bio: Looking for the next PD-1 (L1) "Go Back to Science"

Time of issue : 2019-11-28 15:06:00

From doctors in neurobiology at Columbia University and Albany Medical College to postdoctoral and chief scientists at Amgen, ...

See more information

From doctors in neurobiology at Columbia University and Albany Medical College to postdoctoral and chief scientists at Amgen, ...

2

…

5